| scholarly article | Q13442814 |
| P50 | author | Pierre-Alain Clavien | Q43369501 |
| Peter Neuhaus | Q71350587 | ||
| Antoni Rimola | Q114454882 | ||
| P2093 | author name string | Michael Hall | |
| Björn Nashan | |||
| Mauro Salizzoni | |||
| Dilip Kittur | |||
| Alexander Korn | |||
| CHIC 304 International Liver Study Group | |||
| Elke Ortmann | |||
| Kamal Abeywickrama | |||
| Lawrence Chodoff | |||
| P2860 | cites work | A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation | Q40649309 |
| Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation | Q42985129 | ||
| A longitudinal analysis of hepatitis C virus replication following liver transplantation | Q43047520 | ||
| Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients | Q45049889 | ||
| Disposition and immunodynamics of basiliximab in liver allograft recipients | Q47722055 | ||
| Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group | Q47887130 | ||
| P433 | issue | 2 | |
| P921 | main subject | placebo | Q269829 |
| liver transplantation | Q1368191 | ||
| P304 | page(s) | 132-142 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Liver Transplantation | Q15730498 |
| P1476 | title | Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial | |
| P478 | volume | 8 |
| Q33602527 | A comprehensive review of immunosuppression used for liver transplantation |
| Q91683228 | A risk assessment model of acute liver allograft rejection by genetic polymorphism of CD276 |
| Q33551422 | A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. |
| Q37380304 | Anti-HLA and anti-MICA antibodies in liver transplant recipients: effect on long-term graft survival |
| Q46874610 | Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. |
| Q38998606 | Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis |
| Q37691180 | Antibody immunosuppressive therapy in solid-organ transplant: Part I. |
| Q24194518 | Antibody induction versus corticosteroid induction for liver transplant recipients |
| Q24194087 | Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients |
| Q36337290 | Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials |
| Q53859028 | Basiliximab in lung transplantation: preliminary experience. |
| Q38165224 | Basiliximab: efficacy and safety evaluation in kidney transplantation |
| Q34074790 | Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study |
| Q38062935 | Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review |
| Q44427122 | Blockade of intragraft IL-2 receptor-α by basiliximab is insufficient to prevent activation of liver graft infiltrating cells |
| Q40973756 | CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation. |
| Q36798362 | Current concepts and perspectives of immunosuppression in organ transplantation |
| Q38205739 | Current strategies for immunosuppression following liver transplantation |
| Q62618489 | Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts |
| Q75316178 | Dual monoclonal antibody therapy for the treatment of PTLD? |
| Q45203372 | Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. |
| Q53186309 | Evaluation of Posttransplantation Diabetes Mellitus After Liver Transplantation: Assessment of Insulin Administration as a Risk Factor. |
| Q35711203 | Evolution of immunosuppression in liver transplantation: contribution of cyclosporine |
| Q37355472 | Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients |
| Q45364028 | Hot-topic debate on hepatitis C virus: the type of immunosuppression matters |
| Q35563912 | Immunosuppressive therapy in liver transplantation |
| Q45730578 | Induction immunosuppression in hepatitis C virus-infected liver transplant recipients |
| Q38104751 | Induction immunosuppression in liver transplantation: a review |
| Q44017710 | Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. |
| Q37869042 | Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies |
| Q44465431 | Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials |
| Q37428946 | Invasive mold infections: recent advances in management approaches |
| Q58704499 | Liver transplantation and hepatitis C |
| Q36587253 | Living-donor liver transplantation and hepatitis C |
| Q38737314 | Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. |
| Q36788362 | Management of hepatitis C infection after liver transplantation |
| Q46646250 | Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q37901973 | Neurological complications of transplantation |
| Q36738534 | New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? |
| Q34621443 | Options for induction immunosuppression in liver transplant recipients |
| Q42555714 | Overview of immunosuppression in liver transplantation |
| Q35711483 | Promise of Neoral C2, basiliximab, and everolimus in lung transplantation |
| Q34937253 | Retracted: Comparison of Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Patients with Hepatocellular Carcinoma |
| Q38032009 | Review article: use of induction therapy in liver transplantation |
| Q42213452 | Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis |
| Q84289117 | Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C |
| Q38726102 | Selection and use of immunosuppressive therapies after liver transplantation: current German practice |
| Q37973516 | Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation. |
| Q83831817 | Steroid elimination within 24 hours after orthotopic liver transplantation: effectiveness and tolerability |
| Q36512526 | Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers |
| Q46903622 | The Art and Science of Immunosuppression: the Fifth Annual American Society of Transplant Surgeon's State-of-the-Art Winter Symposium |
| Q84289099 | The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients |
| Q55692477 | The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation. |
| Q46340832 | The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation |
| Q46449513 | The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. |
| Q36675465 | The role of basiliximab induction therapy in organ transplantation |
| Q53854251 | Treatment of steroid-resistant acute liver transplant rejection with basiliximab. |
| Q53851412 | Unique histopathological features of graft biopsies with liver function abnormalities in living donor liver transplant patients receiving basiliximab induction therapy. |
| Q89966929 | Update on Immunosuppression in Liver Transplantation |
| Q35130999 | Use of basiliximab in pediatric liver transplantation for Langerhans cell histiocytosis |
| Q80526260 | [Progress in immunosuppression] |
Search more.